Trial Profile
A observational, prospective, cohort study evaluating effect of belimumab on B cell and T cell alterations in systemic lupus erythematosus (SLE) patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Jan 2017
Price :
$35
*
At a glance
- Drugs Belimumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Pharmacodynamics
- 30 Jan 2017 New trial record